ENTRADA THERAPEUTICS INC (TRDA) Stock News

USA - Nasdaq - NASDAQ:TRDA - US29384C1080 - Common Stock

11.33 USD

+0.3 (+2.72%)

Last: 12/16/2025, 3:05:34 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TRDA Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 days ago - By: The Motley Fool - Mentions: CNTA SKYE PHVS CAMP

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

a month ago - By: The Motley Fool - Mentions: VKTX SKYE PHVS CAMP ...

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

a month ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Zacks Investment Research - Mentions: BRTX

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

4 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

7 months ago - By: Entrada Therapeutics, Inc. - Mentions: BIIB

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

7 months ago - By: Zacks Investment Research - Mentions: BHST

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

8 months ago - By: Zacks Investment Research - Mentions: ETON

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

8 months ago - By: Zacks Investment Research - Mentions: VRTX

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

10 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

10 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

10 months ago - By: Benzinga

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy